Use App
New
Connect your Agent
Trending
News
Earnings
All
DIA
0.28%
SPY
0.07%
QQQ
0.75%
Trending
VKTX
37.00%
XRP
5.44%
BB
2.34%
HBAR
8.74%
DOGE
2.73%
BABA
1.87%
MSOS
8.50%
QNT
12.54%
LLY
0.73%
AMD
0.78%
Feed
News
Sentiment
Earnings
Fundamentals
Info
home
Symbol
GSK
news
Exchange:
NYSE
·
Updated 07:30 PM EDT
GSK News
News
all
press releases
Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
Large-cap healthcare outperformed this week: XLV gained 1.4% through Tuesday, while XBI fell 1.4% and IBB declined 0.5%.
Stocktwits
Full Article
Share to Feed
More News
GSK Inks $750M Deal to Add Experimental Blood Cancer Therapy
GSK's $750M Chimagen deal adds a trispecific TCE to its multiple myeloma portfolio, targeting two tumor antigens simultaneously.
Zacks
INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?
Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.
Zacks
GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
GSK's Jideytro delivers strong first-line NSCLC results, with high response rates and durable disease control supporting a planned FDA filing.
Zacks
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff
GSK's Specialty Medicines are driving growth, but an approaching HIV patent cliff is pushing the company to accelerate its pipeline.
Zacks
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.
Zacks
GSK to Advance mRNA Influenza Vaccine Into Phase III Development
GSK to advance its mRNA flu vaccine into phase III after phase II study has shown stronger immune responses and good tolerability.
Zacks
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.
Zacks
GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit?
GSK's shares are down 14% in six months, but strong Specialty Medicines growth and a robust pipeline may support long-term gains.
Zacks
EC Approves Label Expansion of GILD's Trodelvy in First-line Metastatic TNBC
Trodelvy's latest EU approval with Keytruda expands its first-line metastatic TNBC use, strengthening Gilead???s oncology growth opportunity.
Zacks
1
2
Advertisement
|
Remove ads.
Home
Watchlist
Trending
News
Explore
Profile